Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (170)	11/17/1999 1:42:00 PM
From: Ron Kline	Read Replies (1) \| Respond to of 416

Medi seems to be getting a good boost today. I heard some analyst saying he thinks Medi is good buy even at these prices. I bought some a week ago because I was impressed with the chart, earnings growth, and valueline's good write up on the Co. Looks to be a good long-term holding. RK

To: Pseudo Biologist who wrote (170)	1/16/2000 11:57:00 PM
From: Diane	Read Replies (1) \| Respond to of 416

Does anyone know about the drug mentioned in this article (pleconaril)? I am interested in it's potential impact on MEDI, and also the investment potential of ViroPharma... ViroPharma Licenses Battelle Pulmonary Therapeutics' Delivery Device For Its RSV Antiviral Drugs ViroPharma Advancing Lead Product Candidate Toward Clinical Trials EXTON, Pa., Dec. 21 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM - news) and Battelle Pulmonary Therapeutics, a division of Battelle Memorial Institute, today announced that they have entered into a license agreement using Battelle's inhalation drug delivery device technology. ViroPharma will use Battelle's inhalation technology in combination with ViroPharma's small molecule antiviral drug candidates for the treatment of respiratory syncytial virus (RSV) disease. ViroPharma is responsible for the development, manufacturing and commercialization of all RSV products. ``RSV disease represents a serious health threat to individuals of all ages,' said Claude H. Nash, ViroPharma's president and chief executive officer. ``There is an urgent need for effective therapies for this debilitating disease. By leveraging Battelle Pulmonary Therapeutics' drug delivery technology, which is uniquely suited for use in infants, we expect to be able to administer our RSV antiviral compounds directly to the site of virus infection and to potentially see clinical improvement in these patients. We are looking forward to working with Battelle and to advancing this program into human clinical trials as soon as possible.' ``We are excited about working with ViroPharma,' said Dr. Dennis Cearlock, Battelle's senior vice president and general manager. ``We believe our inhalation technology is well-suited for delivering ViroPharma's antiviral compounds, and that the combination may have a significant positive impact in the treatment of RSV disease.' RSV is a major viral respiratory tract pathogen that often causes pneumonia and bronchiolitis. Infants and young children with underlying conditions such as prematurity, congenital heart disease, bronchopulmonary dysplasia and various congenital or acquired immunodeficiency syndromes are at greatest risk of serious RSV morbidity and mortality. Each year in the U.S., RSV is responsible for an estimated 90,000 hospitalizations and approximately 4,000 deaths among hospitalized infants. RSV is also a major cause of morbidity and mortality in the elderly. Further, certain patient groups are particularly at risk of serious and life-threatening complications arising from RSV infections, including bone marrow transplant patients and patients with chronic obstructed pulmonary disease (including bronchitis and emphysema) and asthma. ViroPharma Incorporated is committed to the commercialization, development and discovery of antiviral pharmaceuticals. The Company is focused on drug development and discovery activities for viral diseases including viral meningitis, viral respiratory infection (VRI, a severe form of the common cold), hepatitis C and RSV disease. ViroPharma's most advanced product candidate, pleconaril, is in late stage clinical development for treatment of picornavirus diseases, including viral meningitis and VRI. Battelle Pulmonary Therapeutics, a division of Battelle Memorial Institute, specializes in pulmonary drug products and medical devices intended to treat respiratory and systemic diseases. Battelle Memorial Institute focuses on product development, technology development, technology commercialization, and laboratory management. Headquartered in Columbus, Ohio, Battelle has annual revenues of nearly $1 billion and more than 60 locations throughout the world. This press release contains forward-looking statements that involve a number of risks and uncertainties, including those relating to the use of Battelle's technology and the initiation of human clinical trials with ViroPharma's product candidates for RSV disease. There can be no assurance that planned clinical trials can be initiated on a timely basis, or at all, or that such trials can be successfully concluded. Investigational pharmaceutical products, such as ViroPharma's product candidates for RSV disease, require significant time and effort for research and development, laboratory testing and clinical testing prior to regulatory approval and commercialization. As a result, all of the activities described in this press release are subject to risks and uncertainties. Neither the FDA nor any other regulatory authority has approved any of ViroPharma's product candidates for commercialization. There can be no assurance that FDA or other regulatory authority approval for any product candidate under development by ViroPharma will be granted on a timely basis or at all. Even if approved, there can be no assurance that such drug candidates will achieve market acceptance. These factors, and other factors that could cause future results to differ materially from the expectations expressed in this press release, include, but are not limited to, those described in ViroPharma's Registration Statement on Form S-3 dated October 21, 1999, filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. SOURCE: ViroPharma Incorporated